Injection Pen May Reduce Injection Fear Among RA Patients Taking Etanercept Biosimilar

The study’s limitations included the lack of a control group due to the nature of an observational study, but all patients had previously used the prefilled syringe. Also, the self-reporting of results can lead to recall bias. Additionally, the number of patients in this study was very small, so the results may not be generalizable to the overall RA population.

However, the fear of injection did decrease among these patients who had previously used prefilled syringes, suggesting this new injection pen for YLB113-002 may be preferred by patients.

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

1. Hibino T, Yoshido T, Sagawa A et al. Qualitative survey-based evaluation of operability and convenience for the etanercept biosimilar YLB113 in a unique injection pen in patients with rheumatoid arthritis. GaBiJournal. 2020; 9(3):100–107.
2. Merck. News release: Indications expanded for Merck’s etanercept biosimilar Brenzys. 2020 Sep 25.
3. U.S. Food & Drug Administration. Etanercept (Enbrel) approval letter. 1998 Nov 2.
4. U.S. Food & Drug Administration. Enbrel (etanercept) label. 1998 Nov 2.
5. U.S. Food & Drug Administration. Enbrel (etanercept) supplement approval for auto-injector. 2017 Sep 14.